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Introduction
Hyperimmunoglobulinemia D and periodic fever
syndrome (HIDS; MIM# 260920) is a rare autosomal
recessive autoinflammatory condition caused by muta-
tions in the MVK gene, which encodes for mevalonate
kinase. There is no standard treatment for HIDS.
Objectives
We report on a 2 year-old Austrian boy with recurrent
episodes of fever, febrile seizures, arthralgias, and spleno-
megaly. Rash and abdominal pain were also seen occasion-
ally. During attacks an acute-phase response was detected.
Clinical and laboratory improvement was seen between
attacks. These findings led to the tentative diagnosis
of HIDS.
Methods
Sequencing of the MVK gene showed a homozygous
c.1129G>A (p.Val377Ile, also known as V377I) mutation
in the child, while the healthy non-consanguineous
parents were heterozygous. The mutation is known to be
associated with HIDS.
Results
Therapy with nonsteroidal anti-inflammatory drugs during
attacks had poor benefit. A further febrile episode resulted
in a status epilepticus. Treatment with canakinumab was
initiated and a final dose of 4 mg/kg every 4 weeks
resulted in the disappearance of febrile attacks and a con-
siderable improvement of patient´s quality of life during a
6-month follow-up period. The drug has been well toler-
ated, and no side effects were observed.
Conclusion
Treatment with canakinumab is a therapeutical option
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